Loading...
Loading...
Browse all stories on DeepNewz
VisitWill CVS Caremark announce divestment of pharmacy operations by end of 2025?
Yes • 50%
No • 50%
Official press releases and corporate announcements from CVS Health
Senators Warren and Hawley Lead Bipartisan Bill to Force PBMs to Divest Pharmacies in 3 Years
Dec 11, 2024, 05:00 PM
A bipartisan group of U.S. lawmakers, led by Senators Elizabeth Warren and Josh Hawley, has introduced legislation aimed at addressing conflicts of interest within the pharmaceutical industry. The proposed bill, known as the Patients Before Monopolies (PBM) Act, would require pharmacy benefit managers (PBMs) and health insurers to divest their ownership of pharmacies within three years. This move is intended to curb the influence of PBMs, which have been accused of manipulating the market, inflating drug prices, and driving small pharmacies out of business. The legislation has garnered support in both the Senate and the House, with Representatives Diana Harshbarger and Jake Auchincloss introducing a companion bill in the House. The bill seeks to establish a firewall within the prescription-drug supply chain, separating those who research, manufacture, prescribe, and dispense drugs from those who manage benefits and insurance. The initiative has led to a decline in health care stocks as investors react to potential changes in business models, particularly affecting companies like CVS Caremark and OptumRx.
View original story
Announces acquisition • 25%
Announces divestiture • 25%
Announces new business strategy • 25%
No major announcement • 25%
CVS Health • 25%
Express Scripts • 25%
OptumRx • 25%
Other • 25%
CVS Caremark • 25%
OptumRx • 25%
Express Scripts • 25%
Other • 25%
Announce internal policy changes • 25%
Face additional lawsuits • 25%
No significant actions taken • 25%
Announce new partnerships or acquisitions • 25%
Yes • 50%
No • 50%
Trust significantly improves • 25%
Trust slightly improves • 25%
Trust remains the same • 25%
Trust declines • 25%
CEO resignation • 25%
Board restructuring • 25%
No change • 25%
Other changes • 25%
Significant increase (>10%) • 25%
Significant decrease (>10%) • 25%
No change or decrease • 25%
Moderate increase (0-10%) • 25%
Not passed • 25%
Passed both Houses • 25%
Passed only in Senate • 25%
Passed only in House • 25%